BindRen (colestilan)
- Region
- 🇪🇺 EU
- Active substance
- colestilan
- Company
- Mitsubishi Pharma Europe Ltd
- Status
- Withdrawn
- Therapeutic area
- Hyperphosphatemia
- EU approval
- Mon 21 Jan 2013
- Application
- EMEA/H/C/002377
- ATC
- V03AE
- Official record
- www.ema.europa.eu
Indication
Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.
Regulatory milestones
No milestones recorded in the last year.
Follow BindRen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.